Combacte LAB-Net: Building a European Laboratory Network for Clinical Trials on Anti-Infectives
Open Access
- 17 May 2021
- journal article
- research article
- Published by Taylor & Francis in Future Microbiology
- Vol. 16 (9) , 635-647
Abstract
LAB-Net, the laboratory network of COMBACTE, has established itself as an indispensable network for clinical trials in infectious diseases that plays a crucial part across 30 clinical studies not o...Keywords
Funding Information
- Innovative Medicines Initiative (115523)
- COMBACTE-NET (FP7/2007-2013)
This publication has 15 references indexed in Scilit:
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trialThe Lancet Infectious Diseases, 2021
- Detection and prevalence of carbapenem-resistant Gram-negative bacteria among European laboratories in the COMBACTE network: a COMBACTE LAB-Net surveyInternational Journal of Antimicrobial Agents, 2019
- Comparison of GeneXpert MRSA/SA ETA assay with semi-quantitative and quantitative cultures and nuc gene-based qPCR for detection of Staphylococcus aureus in endotracheal aspirate samplesAntimicrobial Resistance & Infection Control, 2019
- Can public financing of the private sector defeat antimicrobial resistance?Journal of Public Health, 2018
- To the G20: incentivising antibacterial research and developmentThe Lancet Infectious Diseases, 2017
- EUropean prospective cohort study on Enterobacteriaceae showing REsistance to CArbapenems (EURECA): a protocol of a European multicentre observational studyBMJ Open, 2017
- The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public–private partnerships for the development of new strategies to tackle antibiotic resistanceJournal of Antimicrobial Chemotherapy, 2015
- Rethinking Antibiotic Research and Development: World War II and the Penicillin CollaborativeAmerican Journal of Public Health, 2013
- A comprehensive regulatory framework to address the unmet need for new antibacterial treatmentsThe Lancet Infectious Diseases, 2013
- Pharmaceutical research and development: what do we get for all that money?BMJ, 2012